Gatifloxacin: a new fluoroquinolone

Bibliography

• MACGOWAN AP: Mo x iflox acin (Bay 12-8039): a new methoxy quinolone antibacterial. Exp. Opin. Invest. Drugs (1999) 8:181–199.
   PubMedGoogle Scholar
• ••Comprehensive review.
   Google Scholar
• CHEN DK, McGEER A, DeAZAVEDO JC, LOW DE, THE CANADIAN BACTERIAL SURVEILLANCE NETWORK: Decreased susceptibility of Streptococcus pneumo-niae to fluoroquinolones in Canada. N Eng. J. Med. (1999) 341:233–239.
   PubMed Web of Science ®Google Scholar
• ••Fluoroquinolone resistance.
   Google Scholar
• BLONDEAU JM, ZHAO X, DRLICA K, HANSEN G:Comparison of Moxifloxacin, Levofloxacin and Gatifloxacin by the Mutation Prevention Concentra-tion (MPC) Using Clinical Isolates of Streptococcus pneumoniae (SP). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON, Canada (17–20 September 2000). Abstract.
   Google Scholar
• TORRES C, WENNERSTEN CB, MOELLERING JR,ELIOPOULOS GM: Comparative in vitro activity of gatifloxacin, a new fluoroquinolone antimicrobial, against Gram-positive bacteria. 38th Interscience Confer-ence on Antimicrobial Agents and Chemotherapy San Diego, CA, USA (24–27 September 1998). Abstract E193.
   Google Scholar
• HOELLMAN DB, JACOBS MR, APPELBAUM PC: Antipneu-mococcal activity of gatifloxacin compared to eight other compounds by agar dilution MIC and time-kill testing. 38th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (24–27 September 1998). Abstract E175.
   Google Scholar
• JOHNSON DM, JONES RN, BIEDENBACH DJ, PFALLER MA,DOERN GV, THE QUALITY CONTROL STUDY GROUP: Comparative antimicrobial activity of gatifloxacin tested against Streptococcus species including quality control limits and test method validations. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (24–27 September 1998). Abstract E196a.
   Google Scholar
• JONES RN, PFALLER MA, DOERN GV, BEACH M, SENTRYPARTICIPANT STUDY GROUP: Antimicrobial activity of gatifloxacin, a newer 8-methoxy fluoroquinolone, tested against over 23,000 recent clinical isolates from the SENTRY antimicrobial surveillance program 1997. 38th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (24–27 September 1998). Abstract E194.
   Google Scholar
• ODLAND BA, JONES RN, VERHOEF J, FLUIT A, BEACH ML,THE SENTRY ANTIMICROBIAL SURVEILLANCE GROUP (AMERICAS AND EUROPE): Antimicrobial activity of gatifloxacin (AM-1155, CG5501) and four other fluoro-quinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, latin America, Canada and the United States. Diagn. Microbiol Infect. Dis. (1999) 34:315–320.
   PubMed Web of Science ®Google Scholar
• BLONDEAU JM, VAUGHAN D, LASKOWSKI R, BORSOS S,THE CANADIAN ANTIMICROBIAL STUDY GROUP: Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents. J. Antimicrob. Chemother. (Submitted).
   Google Scholar
• HUCZKO E, KOLEK B, WASHO T, MINASSIAN B, BONNERD, FUNG-TOMC J: In vitro activity of gatifloxacin against anaerobes, Mycophasma, Ureaphasma, and Chlamydia spp 38th Intel-science Conference on Antimi-crobial Agents and Chemotherapy. San Diego, CA, USA (24–27 September 1998). Abstract E182.
   Google Scholar
• THOMSON KS, MOLAND ES, SANDERS CC: Activity ofgatifloxacin against clinical isolates with varying levels of resistance to ciprofloxacin. 39th Intel-science Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA (26–29 September 1999). Abstract 354.
   Google Scholar
• HUCZKO E, VALERA L, CONETTA B, STICKE T, MACKO A,FUNG-TOMC J: Susceptibility of bacterial isolates to gatifloxacin (GAT) and ciprofloxacin (CIP) from the clinical trials during the 1997–98 period. 39th Intersci-ence Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (26–29 September 1999). Abstract 351.
   Google Scholar
• ROBLIN PM, HAMMERSCHLAG MR: In vitro acivity of a new fluororquinolone, gatifloxacin, against Chlamydia pneumoniae and Chlamydia trachomatis. 38th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (24–27 September 1998). Abstract E195.
   Google Scholar
• DUBOIS J, ST PIERRE C: An in vitro susceptibility study of gatifloxacin against Legion ella spp . 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (24–27 September 1998). Abstract E196.
   Google Scholar
• MINASSIAN B, WARR G, KOLEK B, RYAN B, FUNG-TOMC J, BONNER D: In vitro activity of gatifloxacin against Gram-positive aerobic bacteria, including Mycobacte-rium spp 38th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (24–27 September 1998). Abstract E181.
   Google Scholar
• DIEKEMA DJ, JONES RN, ROLSTON KVI: Antimicrobial activity of gatifloxacin compared to seven other compounds tested against Gram-positive organisms isolated at 10 cancer-treatment centers. Diagn. Microbiol. Infect. Dis. (1999) 34:37–43.
   PubMed Web of Science ®Google Scholar
• ROLSTON VI, LEBLANC BM, HO DH: In vitro acivity of gatifloxacin against Gram-positive isolates from cancer patients. 39th Intel-science Conference on Antimi-crobial Agents and Chemotherapy. San Francisco, CA, USA (26–29 September 1998). Abstract 360.
   Google Scholar
• JONES RN, PFALLER MA, DOERN GV, BEACH M, THE SENTRY PARTICIPANTS GROUP: Antimicrobial activity of gatifloxacin tested against 1.676 Gram-positive cocci resistant to ciprofloxacin: a multicenter organism sample from North and South America. 38th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (24–27 September 1998). Abstract E190.
   Google Scholar
• MINASSIAN B, KOLEK B, WASHO T, FUNG-TOMC J, BONNER D: In vitro activity of gatifloxacin against Enterobacteriaceae and non-fermenting Gram-negative bacteria. 38th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (24–27 September 1998). Abstract E180.
   Google Scholar
• ERWIN ME, JONES RN, BARRETT MS, PFALLER MA, HAYVVARD CL, DOERN GV: Comparative antimicrobial activityofgatifloxacin,anew8-methoxyfluoroquinolone, tested against Campylo-bacter jejuni and anerobic bacteria. 38th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (24–27 September 1998). Abstract E191.
   Google Scholar
• EDNIE LM, JACOBS MR, APPELBAUM PC: Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrob. Agents Chemother. (1998) 42:2459–2462.
   PubMed Web of Science ®Google Scholar
• WEXLER HM, MOLITORIS D, FINEGOLD SM: In vitro activity of gatifloxacin against anaerobic bacteria isolated frompulmonary specimens. 39th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (26–29 September 1999). Abstract 361.
   Google Scholar
• KHAN AA, ARAUJO FG, REMINGTON JS: Gatifloxacin isactive against Toxoplasma gondiL 39th Intel-science Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA (26–29 September 1999). Abstract 1848.
   Google Scholar
• PANKUCH GA, JACOBS MR, APPELBAUM PC: Post-antibiotic and post-antibiotic sub-MIC effect of gatifloxacin against Gram-positive and -negative bacteria. 39th Intel-science Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA (26–29 September 1999). Abstract 538.
   Google Scholar
• ZHAO X, XU C, DOMAGALA J, DRLICA K: DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc. Natl. Acad. Sci. USA (1997) 94:13991–13996.
   PubMed Web of Science ®Google Scholar
• ••Mutation prevention concentrations.
   Google Scholar
• BLONDEAU JM, BORSOS S, DRLICA K: Mutation preven-tion concentration of moxifloxacin and levofloxacin against clinical isolates of S. pneumoniae and S. aureus. 39th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (26–29 September 1999). Abstract 032.E.
   Google Scholar
• BREEN J, SKUBA K, GRASELA D: Safety and tolerability of oral gatifloxacin, a new 8-methoxy fluoroquinolone: overview of clinical data. 39th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (26–29 September 1999). Abstract 200.
   Google Scholar
• ZINNER A, GILBERT D, SIMMONS K: Activity of simulated oral dosing of gatifloxacin against Streptococcus pneumoniae in an in vitro dynamic model. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (24–27 September 1998). Abstract E188.
   Google Scholar
• ANDES D, CRAIG A: In vivo pharmacodynamics of gatifloxacin. 39th Intel-science Conference on Antimicro-bial Agents and Chemotherapy. San Francisco, CA., USA (26–29 September 1999). Abstract 191.
   Google Scholar
• YANG H, DAIN R, CLARK J: Gatifloxacin efficacy in an experimental otitis media infection caused by a ciprofloxacin-resistant S. pneumoniae or a Beta-lactamase-positive H. influenzae in a gerbil model. 39th Intel-science Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA (26–29 September 1999). Abstract 1549.
   Google Scholar
• DRAIN R, LAMB L, MEDINA L et al: Gatifloxacin: efficacy against penicillin-resistant Streptococcus pneumo-niaein an experimental murine lung infection model. 38th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (24–27 September 1998). Poster H595.
   Google Scholar
• LUTSAR I, FRIEDLAND IR, WUBBEL L et al.: Pharmacody-namics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother. (1998) 42:2650–2655.
   PubMed Web of Science ®Google Scholar
• NAKASHIMA M, UEMATSU T, KOSUGE K et al: Single- andmultiple-dose pharmacokinetics of AM-1155, a new 6-fluro-8-methoxy quinolone, in humans. Antimicrob. Agents Chemother. (1995) 39:2635–2640.
   PubMed Web of Science ®Google Scholar
• GRASELA DM, LACRETA FP, UDERMAN HD, KOLLIA GD,BIRKHOFER MJ: A dose-escalation study of the safety, tolerance and pharmocokinetics (PK) of intravenous (IV) gatifloxacin in healthy adult subjects. 39th Intersci-ence Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (26–29 September 1998). Abstract 193.
   Google Scholar
• LACRETA FP, KAUL S, KOLLIA GD, DUNCAN FG, RANDALLDM, GRASELA DM: Bioequivalence of 400 mg intrave-nous and oral gatifloxacin in healthy adult subjects. 39th Intel-science Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA (26–29 September 1998). Abstract 192.
   Google Scholar
• SHIBA K, SAKAMOTOM, SAITO A et al.: Effect of ferrous sulfate, teal and milk on absorption of AM-1155, a 6-fluoro-8-methoxy quinolone in humans. 35th Intel-science Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA (17–20 September 1995). Abstract 8.
   Google Scholar
• GOHLER K, STAHLBERG HJ, GUILLAUME M et al.: Safety, tolerance and food effect after single and multiple oral doses of gatifloxacin, a new fluoroquinolone antibi-otic in humans. Anti-infect. Drugs Chemother. (1998) 16 (Suppl. 0:68.
   Google Scholar
• LACRETA FP, KOLLIA G, DUNCAN FG et al.: Effect of a high-fat meal on the bioavailability of gatifloxacin in healthy volunteers. 38th Intel-science Conference on Antimicrobial Agents and Chemotherapy San Diego, CA, USA (24–27 September 1998). Abstract 10.
   Google Scholar
• KANEKO T, SAITO J, IKEDA N et al.: Penetration of AM-1155 into female genital tissues. Can. J Infect. Dis. (1995) 6 (Suppl. C):353.
   Google Scholar
• NABER CK, STEGHAFNER M, KINZIG-SCHIPPERS M et al.: Gatifloxacin: plasma and urine concentrations and penetration into prostatic and seminal fluid after single oral administration of 400 mg in volunteers. 21st International Congress of Chemotherapy. Birmingham, UK (4–7 July 1999). Abstract.
   Google Scholar
• PERRY CM, BALFOUR JAB, LAMB HM: Gatifloxacin. Drugs (1999) 58:683–696.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review.
   Google Scholar
• AOKI N, SHIBA K: Pharmocokinetics of gatifloxacin (AM-1155), a new fluoroquinolone, in elderly patients. 20th International Congress of Chemotherapy (29 June-3 July 1997). Abstract 206–207.
   Google Scholar
• KAWADA Y, KANIMOTOT Y, TAKAHASHI Y et al.: Pharmacokinetics of gatifloxacin (AM-1155) in patients with impaired renal function. Anti-infect. Drug Chemother. (1998) 16 (Suppl. 0:69.
   Google Scholar
• GRASELA DM, CHRISTOFALO B, LACRETA F et al.: Single-dose safety and pharmocokinetics of oral gatifloxacin in subjects with hepatic impairment. 38th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (24–27 September 1998). Abstract 9.
   Google Scholar
• HOSAKA M, YASUE T, FUKUDA H et al.: In vitro and invivo antibacterial activities of AM-1155, a new 6-fluor o-8-methoxy quinolone. Antimicrob. Agents Chemother. (1992) 36:2108–2117.
   PubMed Web of Science ®Google Scholar
• MIYASHITA N, NIKI Y, KISHIMOTO T, NAKAJIMA M, MATSUSHIMA T: In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Antimicrob. Agents Chemother. (1997) 41:1331–1334.
   PubMed Web of Science ®Google Scholar
• ISHIDA K, KAKU M, INFUNE K et al.: In vitro and in vivoactivities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Antimicrob. Agents Chemother. (1994) 34:875–883.
   Web of Science ®Google Scholar
• SATO A, KITAZAWA H, HAAYAKAWA H et al.: Effect of 6-fluoro-8-methoxy quinolone (AM-1155) against chronic airway infection with Pseudomonas aerugi-nosa. J. Antimicrob. Chemother. (1997) 39:217–222.
   PubMed Web of Science ®Google Scholar
• KATO N, KATO H, TANAKA-BANDOH K: Comparative in vitro and in vivo activity of AM-1155 against anaerobic bacteria. J. Antimicrob. Chemother. (1997) 40:631–637.
   PubMed Web of Science ®Google Scholar
• STONER BP, DOUGLAS JM, MARTIN DH et al.: Single dose gatifloxacin (400 mg or 600 mg) vs. single dose ofloxacin (400 mg) in the treatment of uncomplicated gonococcal infections. 39th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (26–29 September 1999). Abstract 1744.
   Google Scholar
• TARSHIS G, MISKIN BM, JONES TM et al.: Oral gatiflox a-cin 400 mg qd vs. oral levofloxacin 500 mg qd in the treatment of uncomplicated skin and soft tissue infections (SSTI). 39th Intel-science Conference on Antimi-crobial Agents and Chemotherapy. San Francisco, CA, USA (26–29 September 1999). Abstract 1075.
   Google Scholar
• SAITO A, SOEJIMA R: The first comparative study with levofloxacin: a double-blind comparative study of gatifloxacin, a new quinolone and levofloxacin in pneumonia. 38th Intel-science Conference on Antimicro-bial Agents and Chemotherapy. San Diego, CA, USA (24–27 September 1998). Abstract 578.
   Google Scholar
• SUZUKI K, KATOH S, HORIBA M et al.: Gatifloxacin, a newer quinolone derivative in the treatment of chroic bacterial prostatitis. Anti-infect. Drugs Chemother. (1998) 16 (Suppl. 0:69.
   Google Scholar
• KAWADA Y, SAITO I, HIROSE T et al.: Dose finding studyof AM-1155 in complicated urinary tract infections. Can. J. Infect. Dis. (1995) 6 (Suppl.
   Google Scholar
• FOGERTY C, MCADOO MA, PASTER RZ, AUDET MC, MACKO A, BREEN JD: Comparison of once-daily gatifloxacin 400 mg po for 10 days with twice-daily clarithromycin 500 mg po for 14 days in subjects with acute maxillary sinisitis: a multicenter phase III study. 39th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (26–29 September 1998). Abstract 169.
   Google Scholar
• SISNIEGA JA, JONES RW, KAMINSZCZIK G et al.: Treatingacute, uncomplicated bacterial sinusitis with gatifloxacin. j Resp. Dis. (1999) 2 (Suppl.):S11–S16.
   Google Scholar
• DEABATE CA, MCIVOR RA, SKUBA K, PIERCE PF: Gatifloxacin (GAT) 400 mg qd vs cefuroxime axetil (CEF) 250 mg bid in the treatment of acute exacerba-tions of chronic bronchitis (AECB). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA (26–29 September 1998). Abstract 177.
   Google Scholar
• DOWELL ME, MAYER H, FOGART CM: A randomized,double-blind, multicenter, comparative study of gatifloxacin 400 mg W and po vs. ceftriaxone ± erythromycin in the treatment of community-acquired pneumonia requiring hospitalization. 39th Intel-science Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA (26–29 September 1999) Abstract 2241.
   Google Scholar
• RICHARD GA, MATHEW CP, KIRSTEIN JM et al.: Single(400 mg) and multiple (200 mg QD) dose oral gatifloxacin (GAT) vs multiple (100 mb bid) dose oral ciprofloxacin (CIP) in the treatment of acute uncomplicated urinary tract infection (UTI) in women. Bristol-Myers Squibb, Princetone (1999). Data on file.
   Google Scholar